

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7757404

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	NUNC PRO TUNC ASSIGNMENT
<b>EFFECTIVE DATE:</b>	09/14/2005
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
WINSTON LABORATORIES, INC.	09/14/2005
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	GIDEON PHARMACEUTICALS, INC.
<b>Street Address:</b>	100 N. FAIRWAY DR., SUITE 134
<b>City:</b>	VERNON HILLS
<b>State/Country:</b>	ILLINOIS
<b>Postal Code:</b>	60061
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	9238017
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)610-5744
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	3123718039
<b>Email:</b>	jbernstein@eloracpharma.com
<b>Correspondent Name:</b>	JEFFREY BERNSTEIN
<b>Address Line 1:</b>	100 N. FAIRWAY DR., SUITE 134
<b>Address Line 4:</b>	VERNON HILLS, ILLINOIS 60061
<b>NAME OF SUBMITTER:</b>	JEFFREY R. BERNSTEIN
<b>SIGNATURE:</b>	/Jeffrey R. Bernstein/
<b>DATE SIGNED:</b>	01/24/2023
This document serves as an Oath/Declaration (37 CFR 1.63).	
<b>Total Attachments: 6</b>	
source=Winston Gideon Assignment Agreement 09-14-05#page1.tif	
source=Winston Gideon Assignment Agreement 09-14-05#page2.tif	
source=US Patent 9,238,017 B2#page1.tif	
source=US Patent 9,238,017 B2#page2.tif	
source=US Patent 9,238,017 B2#page3.tif	



## ASSIGNMENT AND AGREEMENT

FOR VALUE RECEIVED, Winston Laboratories, Inc. ("Winston"), a Delaware corporation, with a principal place of business at 100 Fairway Drive, Suite 134, Vernon Hills, Illinois 60061, its successors, assigns and legal representatives hereby sell, assign and transfer to Gideon Pharmaceuticals, Inc., a Delaware corporation, with a principal place of business at 100 Fairway Drive, Suite 134, Vernon Hills, Illinois 60061, its successors, assigns and legal representatives, the entire right, title and interest, for all countries in and to certain inventions relating to improvements in COMPOSITIONS WITH REDUCED HEPATOTOXICITY, described in an application for Letter Patent of the United States and executed on SEPT 14, 2005 and all the rights and privileges under any and all Letters Patent that may be granted therefore, including any and all continuations, continuations-in-part, divisions, reissues, re-examinations, and extensions thereof.

Winston requests that any and all patents for said inventions be issued to said assignee, its successors, assigns and legal representatives, or to such nominees as it may designate.


Winston agrees that, when requested, Winston will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, and do all acts which may be necessary, desirable or convenient for securing and maintaining patents for said inventions in any and all countries and for vesting title thereto in said assignee, its successors, assigns and legal representatives or nominees.

Winston authorizes and empowers the said assignee, its successors, assigns and legal representatives or nominees, to invoke and claim for any application for patent or other form of protection for said inventions filed by it or them, the benefit of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it, and to invoke and claim such right of priority without further written or oral authorization from me.

Winston hereby consents that a copy of this assignment shall be deemed a full legal and formal equivalent of any assignment, consent to file or like document which may be required in any country for any purpose and more particularly in proof of the right of the said assignee or nominee to claim the aforesaid benefit of the right or priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it.

Winston covenants with said assignee, its successors, assigns and legal representatives that the rights and property herein conveyed are free and clear of any encumbrance, and that Winston has full right to convey the same as herein expressed.

Signed at VERNON HILLS, IL this 14 day of SEPT., 2005.

  
Joel E. Bernstein for Winston Laboratories, Inc.

Signed in our presence and acknowledged to be an assignment of the application (invention) hereinabove referred to.

Witness: Melissa Turner

Date: Sept 14, 2005

Witness: Alan Davies

Date: Sept. 14 2005



US009238017B2

(12) **United States Patent**  
**Bernstein**(10) **Patent No.:** **US 9,238,017 B2**(45) **Date of Patent:** **Jan. 19, 2016**(54) **COMPOSITIONS WITH REDUCED  
HEPATOTOXICITY**(75) Inventor: **Joel E. Bernstein**, Deerfield, IL (US)(73) Assignee: **Winston Laboratories, Inc.**, Vernon Hills, IL (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 178 days.

(21) Appl. No.: **13/197,581**(22) Filed: **Aug. 3, 2011**(65) **Prior Publication Data**

US 2011/0288099 A1 Nov. 24, 2011

**Related U.S. Application Data**

(62) Division of application No. 10/813,760, filed on Mar. 31, 2004, now abandoned.

(51) **Int. Cl.****A61K 31/198** (2006.01)**A61K 31/167** (2006.01)**A61K 47/18** (2006.01)**A61K 9/00** (2006.01)(52) **U.S. Cl.**CPC ..... **A61K 31/198** (2013.01); **A61K 9/0019** (2013.01); **A61K 31/167** (2013.01); **A61K 47/18** (2013.01); **A61K 47/183** (2013.01)(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

## U.S. PATENT DOCUMENTS

3,983,250	A	9/1976	Abdallah et al.
4,181,719	A	1/1980	Margetts et al.
4,314,989	A	2/1982	Rosen
4,401,657	A	8/1983	Kashiwabara et al.
4,526,788	A	7/1985	Murdock et al.
4,581,348	A	4/1986	Schwartz et al.
4,656,159	A	4/1987	McPherson et al.
4,837,239	A	6/1989	Benjamin et al.
5,059,592	A	10/1991	Yokota et al.
5,284,861	A	2/1994	Lobisch et al.
5,474,757	A	12/1995	Yang
5,478,815	A	12/1995	Ogata et al.
5,597,585	A	1/1997	Williams et al.
5,804,567	A	9/1998	Cheng et al.
5,994,410	A	11/1999	Chiang et al.
6,048,846	A	4/2000	Cochran
6,465,511	B1	10/2002	Kazmierski et al.
6,468,967	B1	10/2002	Oelson et al.
6,673,831	B1	1/2004	Tobert
6,733,797	B1	5/2004	Summers
6,881,401	B1	4/2005	Yu et al.
7,371,388	B1	5/2008	Ruben et al.
7,557,142	B2	7/2009	Campbell
2009/0124606	A1	5/2009	Gacsalyi et al.

## FOREIGN PATENT DOCUMENTS

EP 0285343 10/1988

## OTHER PUBLICATIONS

Andrade et al., "Assessment of Drug-Induced Hepatotoxicity in Clinical Practice: A Challenge for Gastroenterologists," *World J. Gastroenterol.*, vol. 21:13(3), pp. 329-340 (2007).Anjum et al., "Sublethal effects of hexavalent chromium on the body growth rate and liver functions enzymes and phenobarbiton-pretreated and promethazine-pretreated rabbits," *J. Environ. Pathol. Toxicol. Oncol., Abstract*, vol. 16:1, pp. 51-59 (1997).Azari et al., "Effects of Intraperitoneal Injection of Rofecoxib in a mouse model of ALS," abstract, *EP Jnl. of Neurol.*, vol. 12:5, pp. 357-364 (2005).DeNoon, "New Warning Labels for Acetaminophen," *WebMD Health, WebMD Medical News Archive* (2002).

"Equivalent Surface Area Dosage Conversion Factors," Guidance Posted Aug. 2007.

"FDA Panel Wants Stronger Acetaminophen Warnings," *SCRIP*, p. 2784 (2000).Hoekstra et al., "Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis," *Annals of Rheumatic Diseases, British Medical Association, London*, 62 (5) 423-426 (2003)."Intraperitoneal Injection," [www.en.wikipedia.org/wiki/intraperitoneal](http://www.en.wikipedia.org/wiki/intraperitoneal), 2008.Kroger et al., "Nicotinamide and Methionine Reduce the Liver Toxic Effect of Methotrexate," *General Pharmacology*, vol. 33, pp. 203-206 (1999).Kroger et al., "Protection from acetaminophen-induced liver damage by the synergistic action of low doses of the poly (ADP-ribose) polymerase-inhibitor nicotinamide and the antioxidant N-acetylcysteine or the amino acid L-methionine," *General Pharmacology*, vol. 28:2, pp. 257-263 (1997).Laborda et al., "Nephrotoxic and hepatotoxic effects of chromium compounds in rats," *Bull. Environ. Contain. Toxicol.*, Abstract, vol. 36:3, pp. 332-336 (1986).Lee, *N. England J. Med.*, vol. 394:5, pp. 474-485 (2003).Legon'kova et al., "The effect of nicotinamide, methionine and alpha-tocopherol on the liver conjugating and mono-oxygenase systems and on lipid peroxidation in hepatitis-hepatitis in rats," *Eksp Klin Farmakol*, Abstract, vol. 60:2, pp. 68-71 (1997).Martindale, *The Complete Drug Reference*, 33rd Edition, Pharmaceutical Press, Chelators Antidotes and Antagonists, p. 1012 (2002). Milano et al., *Antimicrobial Agents and Chemotherapy*, pp. 117-121 (1997).Stolberg, "Warnings Sought for Popular Painkiller," *New York Times* (2002).Ulbricht et al., "An evidence-based systematic review of herb and supplement interactions by the natural standard research collaboration," *Expert Opinion*, vol. 5:5, pp. 719-728 (2006).Vale et al., "Paracetamol (Acetaminophen) Poisoning," *The Lancet*, vol. 346, pp. 547-552 (1995).Willett et al., "Workshop Overview: Hepatotoxicity Assessment for Botanical Dietary Supplements," *Society of Toxicology*, pp. 1-16 (2004).Wright et al., "Deaths from Low Dose Paracetamol Poisoning," *British Medical Journal (England)*, vol. 317, p. 1656 (1998).*Primary Examiner* — L. R. Draper(74) *Attorney, Agent, or Firm* — Barnes & Thornburg LLP; Alice O. Martin(57) **ABSTRACT**

Pharmaceutical compositions of hepatotoxic compounds are provided in which the hepatotoxicity of the compounds is mitigated by including quantities of nicotinamide and methionine in the composition. Folic acid also can be included to further mitigate the hepatotoxic effects. The hepatotoxic compounds can include acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, flucanazole, divalproex sodium, and valproic acid.

7 Claims, No Drawings

**PATENT****REEL: 062464 FRAME: 0874**

1

## COMPOSITIONS WITH REDUCED HEPATOTOXICITY

### CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This patent application is a Divisional of copending U.S. patent application Ser. No. 10/813,760, filed Mar. 31, 2004, the contents of which are incorporated herein by reference in their entirety.

### FIELD OF THE INVENTION

This invention relates to compositions of pharmaceutical compounds having hepatotoxicity, in which compositions the hepatotoxicity is mitigated. More particularly, this invention relates to compositions of hepatotoxic compounds such as acetaminophen, methotrexate, statin drugs, niacin, divalproex sodium, valproic acid or fluconazole, each of which is known to have hepatotoxic properties, in which compositions the hepatotoxicity of the compound is mitigated.

Acetaminophen is the active metabolite of phenacetin, a drug whose use extends back to the 1880's. Although acetaminophen was first used as an analgesic and antipyretic in 1893, it did not achieve widespread use until after 1949. For many years, acetaminophen was used as a second-line choice to aspirin as an analgesic/antipyretic, but the elucidation of the relationship between aspirin use and Reye's Syndrome and the recognition of aspirin's propensity to produce gastrointestinal bleeding vaulted acetaminophen into its current day position as the analgesic/antipyretic of first choice in both children and adults. While acetaminophen is usually well tolerated, its use can be accompanied by a very serious adverse effect—potentially fatal hepatic necrosis. Hepatic necrosis with acetaminophen is largely confined to two groups of patients: 1. Patients who ingest acute overdoses or who chronically utilize high dosage regimens of acetaminophen. 2. Ingestion of acetaminophen by alcoholics or in combination with alcohol ingestion. It has been reported that more than 26,000 patients per year are hospitalized in the U.S. for acetaminophen induced hepatic necroses, and of these, more than 400 die each year. Many of these overdoses are the result of suicide attempts, but reports indicate that more than 2,000 hospitalizations and 100 deaths a year were attributable to non-intentional acetaminophen overdoses. In fact, an Advisory Panel of the U.S. Food and Drug Administration has recommended that new warning language be added to the label of acetaminophen containing products concerning the danger of hepatic necroses.

Methotrexate, an inhibitor of cell metabolism, has been utilized for several decades as a therapeutic agent widely used in several different diseases including rheumatoid arthritis and psoriasis. While methotrexate administration is associated with various other side effects, severe and sometimes fatal liver toxicity is a significant limiting factor in its therapeutic usefulness. Atorvastatin, simvastatin and other cholesterol reducing agents of the "statin" family are the most widely used pharmaceuticals in the world. In spite of their widespread use, liver toxicity is a significant problem, and patients with a history of old or active hepatitis must avoid these drugs even if they could benefit from their cholesterol lowering actions. Niacin (also known as nicotinic acid or vitamin B<sub>3</sub>), another agent frequently employed as a cholesterol lowering agent, is also associated with a high incidence of liver toxicity. Fluconazole, a potent antifungal agent, and

2

divalproex sodium and valproic acid, widely used antiepileptics are three other agents whose clinical use is limited by their hepatotoxicity.

The concerns about the hepatic toxicity of acetaminophen, methotrexate, the "statin" cholesterol lowering agents, niacin, fluconazole, divalproex sodium and valproic acid, prompted me to search for a substitute or a mixture of substances that in combination with any of these drugs would substantially reduce the risk of hepatic toxicity without adversely affecting the therapeutic benefits conferred by these drugs. In reviewing the scientific literature, I learned that nicotinamide (also known as niacinamide), which is the amide of vitamin B<sub>3</sub> (niacin), and methionine, an essential amino acid which is a DL racemic mixture of D & L methionine, have been used in very high dosages to prevent liver damage from acetaminophen or methotrexate. These drugs have been administered as single large doses or multiple large doses over a short (usually 24 hr) period. Published dosages of methionine for such usage range from about 2.5 gm to over 21 gm administered as a single dose for over 24 hours. Wright, B., Crowe, M., *British Medical Journal* (England), vol. 317, Dec. 12, 1998, p. 1656; Vale, J. A., Proudfoot, A. T., *The Lancet*, 1995, vol. 346, pp. 547-52. Similarly, doses of nicotinamide utilized for a similar purpose have ranged from about 2 gm to 7 gm per 24 hours. Kroger, H., et al., *General Pharmacology* 33 (1999) 203-206.

I have discovered, surprisingly, that nicotinamide and methionine can be administered in combination with hepatotoxic pharmaceutical compounds such as acetaminophen, methotrexate, a "statin" cholesterol lowering agent, fluconazole, divalproex sodium or valproic acid, in substantially lower doses than disclosed in the prior art, and when administered as such, can provide a substantive protective effect against the hepatotoxicity of these agents without negatively affecting their beneficial therapeutic activity. I have furthermore discovered that by adding a modest amount of folic acid to the nicotinamide and methionine mixture, in combination with hepatotoxic pharmaceutical compounds such as acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium, valproic acid, and related drugs, I can achieve a therapeutic product which provides the therapeutic benefits of each of these agents with almost no potential for liver toxicity.

It is thus the object of the invention to provide pharmaceutically acceptable compositions of hepatotoxic therapeutic drugs such as acetaminophen, methotrexate, the "statins," niacin, fluconazole, divalproex sodium, valproic acid, and related drugs, which compositions provide the therapeutic benefits of the active drug with markedly reduced potential for serious hepatotoxicity.

### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In accordance with the invention, compounds having known hepatotoxic properties are formulated into compositions in which the hepatotoxic properties are mitigated. The compositions can include a standard dose of the hepatotoxic compound, together with relatively low dosages of nicotinamide and methionine. Low dosages of folic acid also can be added to the compositions to further mitigate the hepatotoxic properties.

Specific embodiments of the invention can be in the form of formulations of acetaminophen together with mixtures of low dosages of nicotinamide and methionine, or together with low dosages of nicotinamide, methionine and folic acid; or formulations of methotrexate together with mixtures of low dos-

PATENT

REEL: 062464 FRAME: 0875

3

ages of nicotinamide and methionine, or together with low dosages of nicotinamide, methionine and folic acid. These formulations are incorporated into pharmaceutically acceptable vehicles for use in humans and animals. Similarly, formulations of atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium or valproic acid each can be formulated into pharmaceutically acceptable vehicles for use in humans and animals together with mixtures of low dosages of nicotinamide and methionine, or together with low dosages of nicotinamide, methionine and folic acid. Such formulations include those suitable for oral administration such as capsules, tablets, caplets, or liquid solutions or suspensions, as well as sterile solutions or suspensions suitable for intradermal, subcutaneous, intramuscular, intravenous or intrathecal injection.

In each of the foregoing formulations, whether for oral ingestion or for injection, when combined with standard dosages of either acetaminophen (80 mg-1000 mg per single dose form, e.g. single capsule, single tablet, etc.), methotrexate (2.5 mg-250 mg per single dose form), atorvastatin or simvastatin (5 mg-100 mg per single dose form), niacin (250 mg-1000 mg per single dose form), fluconazole (10 mg-250 mg per single dose form), divalproex sodium (100 mg-750 mg per single dose form), and valproic acid (25 mg-500 mg per single dose form), methionine may be present in the amount of about 5 mg to about 500 mg per single dose form, and preferably about 10 mg to 100 mg per single dose form, and nicotinamide may be present in the amount of about 10 mg to 500 mg per single dose form, and preferably about 25 mg to about 200 mg per single dose form. When folic acid is included in the standard dose formulation, folic acid may be present in the amount of about 50 mcg to about 5 mg, and preferably about 500 mcg to 1 mg, per single dose form.

Suitable pharmaceutical vehicles for the combinations of hepatotoxic compounds such as acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium or valproic acid, with hepatotoxicity mitigators methionine, nicotinamide and folic acid, and methods of preparing such formulations as are within the scope of the invention, will be readily apparent to and understood by those skilled in the art.

The compositions of the instant invention will be more readily comprehended from the following examples:

#### EXAMPLES

##### Example 1

Two tablets, comprised of 500 mg acetaminophen, 50 mg methionine, and 25 mg nicotinamide, are administered to patients with painful osteoarthritis four times daily for 12 weeks producing substantial relief of joint pain without evidence of any hepatotoxicity.

##### Example 2

Capsules are prepared each containing by weight 325 mg acetaminophen, 50 mg methionine, 50 mg nicotinamide, and 500 mcg folic acid. One to two of such capsules are administered to patients with osteoarthritis or fibromyalgia pain four to six times daily for 6 months for relief of joint or soft tissue pain without evidence of damage to the patients' livers.

##### Example 3

Two caplets each containing 500 mg acetaminophen, 200 mg methionine, and 100 mg nicotinamide are administered

4

four times daily for twelve (12) weeks to patients with osteoarthritis for relief of osteoarthritis pain without evidence of liver damage.

##### Example 4

Tablets are prepared each containing 2.5 mg methotrexate, 100 mg methionine, 100 mg nicotinamide and 100 mcg folic acid. Two of such tablets are administered to patients with psoriasis of the skin twice daily for 6 months. Such patients demonstrate improvement in their psoriatic lesions without evidence of serious methotrexate-induced liver damage.

##### Example 5

Tablets containing 250 mg divalproex sodium, 250 mg methionine and 100 mg nicotinamide by weight are administered twice daily to patients with migraine headaches to prevent or diminish the severity of migraine headaches without evidence of serious liver damage.

##### Example 6

Capsules are prepared each containing by weight 10 mg atorvastatin, 500 mg methionine, 100 mg nicotinamide, and 1.0 mg folic acid and administered to patients once daily. Such patients have lower serum cholesterol and triglycerides without evidence of significant alteration in their liver functions.

##### Example 7

An oral suspension containing 10 mg/ml fluconazole, 25 mg/ml methionine and 20 mg/ml nicotinamide is administered to children for treatment of oropharyngeal candidiasis at a dosage of 2-12 mg/kg per day for 3 weeks with a substantially lessened risk of liver toxicity than with standard fluconazole suspensions.

What is claimed is:

1. A method of mitigating the hepatotoxicity of a hepatotoxic compound, the method comprising:

formulating a composition of the hepatotoxic compound by combining a quantity of the hepatotoxic compound with a quantity of nicotinamide, a quantity of methionine, and a quantity of folic acid into a single individual dosage form selected from the group consisting of a capsule, a tablet or an oral solution,

and further administering the individual dosage form containing the hepatotoxic compound, nicotinamide, folic acid, and methionine to a patient in need of the hepatotoxic compound,

wherein the hepatotoxic compound is selected from the group consisting of acetaminophen, atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium, and valproic acid.

2. The method of claim 1 wherein said composition is formulated such that for each dose of the hepatotoxic compound in the composition, the nicotinamide is present in the amount of 5-500 mg, and the methionine is present in the amount of 25-500 mg.

3. The method of claim 2 wherein said nicotinamide is present in the amount of 25-200 mg per dose of the hepatotoxic compound.

4. The method of claim 2 wherein said methionine is present in the amount of 10-100 mg per dose of the hepatotoxic compound.

5

6

5. The method of claim 1 wherein said folic acid is present in the amount of 50 mcg-5 mg per dose of the hepatotoxic compound.

6. The method of claim 5 wherein said folic acid is present in the amount of 500 mcg-1 mg per dose of the hepatotoxic compound.

7. The method of claim 1, wherein said acetaminophen is present in the amount of 80 mg-1000 mg per dose.

\* \* \* \* \*